Syndrome of Inappropriate Antidiuresis (SIAD/SIADH) from Ovarian Cancer
The most likely cause of hyponatremia in this patient is SIAD (syndrome of inappropriate antidiuresis) secondary to ectopic vasopressin secretion from her ovarian cancer.
Diagnostic Reasoning
The laboratory findings are pathognomonic for SIAD:
- Low serum osmolarity (252 mmol/kg) with inappropriately concentrated urine (545 mmol/kg) - this is the hallmark finding
- Euvolemic clinical status - excludes hypervolemic causes (heart failure, cirrhosis) and hypovolemic causes (dehydration, diuretics)
- **Urine sodium <20 mmol/L** - while typically SIAD shows urine sodium >20-40 mmol/L, this lower value doesn't exclude the diagnosis, particularly in the context of all other confirmatory findings
- Severe hyponatremia (123 mmol/L) with serum osmolarity <275 mmol/kg confirms hypotonic hyponatremia
The clinical context strongly supports paraneoplastic SIAD: ovarian cancer is a documented cause of ectopic vasopressin production 1, 2. Ovarian serous carcinomas with neuroendocrine differentiation can produce antidiuretic hormone, demonstrable by immunohistochemistry in tumor cells 1.
Why Not Other Causes?
- Not hypervolemic hyponatremia: Despite bilateral malignant effusions, she is clinically euvolemic. The effusions are malignant (not from volume overload), and her albumin of 33 g/L is only mildly reduced, insufficient to cause significant third-spacing 3
- Not hypovolemic: Clinical euvolemia and the concentrated urine with low urine sodium argue against true volume depletion
- Not hypothyroidism or adrenal insufficiency: These must be ruled out biochemically, but the clinical presentation with known malignancy makes paraneoplastic SIAD most likely 4, 5
Clinical Significance
Hyponatremia in cancer patients is associated with worse progression-free survival and overall survival across multiple cancer types 6, 7. In ovarian cancer specifically, SIAD represents a paraneoplastic syndrome that may indicate more aggressive disease biology 1, 2.
Management Approach
For chronic, asymptomatic or mildly symptomatic hyponatremia from SIAD:
- Fluid restriction is first-line therapy (typically 800-1000 mL/day) 7, 4
- Increased solute intake (urea, salt tablets) enhances free water excretion 4
- Avoid 0.9% saline - acts as hypotonic solution in SIAD and can paradoxically worsen hyponatremia 4
If fluid restriction fails:
- Vasopressin V2-receptor antagonists (vaptans) like tolvaptan provide mechanism-based therapy by blocking vasopressin effects in renal collecting ducts, promoting aquaresis 7, 8
- Vaptans have shown unexpected antiproliferative effects in vitro against cancer cells 6
Critical caveat: Correction rate must not exceed 8 mEq/L over 24 hours to prevent osmotic demyelination syndrome 4. Consider concurrent desmopressin administration in high-risk patients to prevent overly rapid correction 4.
Treat the underlying malignancy: Hyponatremia may serve as a surveillance biomarker alongside tumor markers; resolution with cancer treatment and recurrence with disease progression has been documented 2.